Scleroderma Foundation eLetter

Archive

"Aerobic Exercise May Help With Autoimmune Disease-Related Fatigue"

(originally published in the "Journal of Advanced Nursing" 2006)

NEW YORK (Reuters Health) Dec 25 - Increasing amounts of low impact aerobic exercise may help individuals with the fatigue that often accompanies chronic autoimmune conditions, such as multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis, according to a recent report.


Friday, February 9, 2007– Issue #180	eLetter Archive

Topical Nitroglycerin Gel Shows Promise as Treatment Advance for Raynaud's

This headline from last week's eLetter (#179) elicited many e-mails asking questions about the gel's availability. In response to the e-mails, we found that this medication is still in clinical trials and is not available yet. It is in its second phase III trial. It is possible that after this trial the company will present to the FDA for approval. We do not know when/if the gel will become available for use in treatment.

FDA Proposes Labeling Changes to Over-the-Counter Pain Relievers

Recently, the Food and Drug Administration (FDA) proposed to amend the labeling regulations on over-the-counter (OTC) Internal Analgesic, Antipyretic, and Antirheumatic (IAAA) drug products to include important safety information regarding the potential for stomach bleeding and liver damage and when to consult a doctor.

Progressive Skin Changes on the Forehead of a 16-Year-Old Girl

(May require free registration to MedscapeToday.com.)

Space Technology Benefits Medical Community

Hopkins Team Field Tests Monitor to Characterize Raynaud’s Disease.

Study: Blood Viscosity Shown to Be Elevated in Scleroderma Patients

Rheologics Technologies, Inc. (PINKSHEETS: RTGI) ("Rheologics," the "Company"), the leader in the study of blood viscosity and its relationship to vascular diseases, announced recently the results of a study performed at the University of Chicago using the Rheolog(R), the Company's proprietary blood viscometer.

Improved Long-Term Outcome With Remodulin Reported in European Respiratory Journal and Rapid Transition to Remodulin Reported in Journal of Cardiovascular Pharmacology

United Therapeutics Corporation (NASDAQ:UTHR) announced the publication of two important studies:

Long-term outcome in pulmonary arterial hypertension patients with subcutaneous treprostinil. (Eur Respir J 2006:1195-1203); and

Rapid Switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. (J Cardiovasc Pharm 2007:49(1): 1-5).

Upcoming Events

	February 11 (Sun.): Southeast Florida Chapter's Theater Event (Boca Raton, Fla.)
	February 11 (Sun.): Michigan Chapter Patient Education Days (Farmington Hills, Mich.)
	July 20–22 (Fri.–Sun.): Scleroderma Foundation's National Conference (Philadelphia, Penn.)
SF Calendar

Scleroderma Foundation, 300 Rosewood Drive, Suite 105, Danvers, MA 01923
Phone 978-463-5843 · 800-722-HOPE (4673)

If you cannot view the eLetter, or the links do not work, you can read it on the Web at www.scleroderma.org/e-letters/eLetter_180.htm. If someone has forwarded this eLetter to you, and you wish to subscribe to this FREE weekly publication, go to www.scleroderma.org/e_letter_signup.shtm.